Excellos Announces the Launch of ‘Excellos 360’ Technology at Advanced Therapies Week

Anna Osborne
18 January 2023
SHARE NOW
ATW
Cell Therapy
GMP
Scaling Up
Excellos 360 will employ the Company’s novel technology and unique approach to immunotherapy development offering the deep characterization of immune cell starting material and the manufacture of intermediates and partner’s cells.

San Diego-based CDMO, Excellos, has announced the launch of its new ‘Excellos 360’ technology at Phacilitate’s Advanced Therapies Week, Miami Beach Convention Center, 17th January 2023.

Excellos 360 will employ the Company’s novel technology and unique approach to immunotherapy development offering the deep characterization of immune cell starting material and the manufacture of intermediates and partner’s cells.

This new platform will offer support to all stages of therapeutic development from RUO to GMP, with its CDMO capabilities.

How are you enjoying this news article? Let us know your thoughts, here >>

“Excellos 360 opens a new chapter in immunotherapy development through superior characterization of starting materials and rigorous development and manufacturing techniques. In developing new partnerships based on the Excellos 360 service offering, we are looking forward to accelerating the manufacturing and development of cell and gene therapies, ultimately getting life-saving cancer treatments to patients, faster,” commented David Wellis CEO, Excellos.

Similarly, to Excellos’ RUO and cGMP cellular products and services, Excellos 360 is built on the foundations of the San Diego Blood Bank and aims to allow therapeutic developers to improve the accessibility and ease of manufacturing and use of their immunotherapy treatments.

Excellos 360’s proprietary services improve the potency of cell-based treatments and overcome the limitation of variable results that often limit the treatment of cancer, to improve outcomes.

Variability can be caused by tumor/host biology, inherent tumor resistance mechanisms, and the cell therapy product itself.

Excellos 360 reduces clinical response variability through a detailed screening that creates an immune cell profile for each donor and assesses the metabolic and effector potential of their cells. This has the potential to not only improve therapeutic outcomes but also increase effectiveness at lower dosages and lower the costs of goods associated with the therapeutic manufacture.

This platform also utilizes the principles of Quality by Design (QbD) to continually evaluate factors of variability throughout the manufacturing workflow, whilst simultaneously considering costs and yield.

“The combined application of Excellos’ deep cell characterization and QbD methodologies results in a solution for therapeutics developers looking to reduce the variability in patient outcomes. This is a solution that can be employed in parts or as an entire end-to-end solution, customizable to partners’ specific needs,” adds Wellis.

“Excellos 360 excites us as we can offer capabilities not previously available in the industry, which creates extensive partnership opportunities,” he concluded.

You can find out more from the Excellos team at booth 610, on the exhibition floor.

Source: Excellos press release

Join us at Advanced Therapies Week >>


While we have you…

We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.